SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

PROQUAD

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already on the market since 2005.
Why 3/10
ProQuad is an already-approved, marketed vaccine with no pending PDUFA date, Advisory Committee meeting, or pivotal readout scheduled in the next 12 months. It is a mature product within Merck's massive $67 billion portfolio, and the combined MMRV franchise (ProQuad + M-M-R II + Varivax) generates only about $538 million annually, less than 1% of total revenue. No binary catalyst exists to drive a meaningful share-price move.
Actionable Insight NEUTRAL

ProQuad has no scheduled PDUFA date, AdComm, or pivotal readout in the next 12 months. As a mature, approved vaccine, its commercial trajectory will be driven by routine pediatric immunization rates and competition from GSK's Priorix, not by any binary catalyst. For MRK investors, the drug is a negligible revenue contributor within a $67 billion portfolio dominated by Keytruda and Gardasil.

Price Chart

Loading chart...

Executive Summary

ProQuad is Merck's combination vaccine (MMRV) that protects children aged 12 months to 12 years against measles, mumps, rubella, and varicella (chickenpox). It was first FDA-approved in September 2005 and is a well-established, commercially marketed product. Recent label updates include FDA approval of an intramuscular route of administration (March 2023) and a concomitant-use supplement (November 2024). ProQuad is grouped with Merck's other pediatric vaccines (M-M-R II and Varivax) for reporting; that combined franchise generated roughly $538 million in 2026, a tiny fraction of Merck's ~$67 billion total revenue. There are no pending regulatory decisions or pivotal readouts for this drug, making it a non-event for MRK shareholders.

How It Works

ProQuad is a combination vaccine that contains weakened live forms of the measles, mumps, rubella, and varicella (chickenpox) viruses. When injected, it stimulates the child's immune system to produce antibodies against all four diseases without causing the illnesses themselves, providing long-term protection.

Trial Status

ProQuad was initially FDA-approved in September 2005. The FDA approved an intramuscular (IM) route of administration in March 2023, and a supplemental BLA for concomitant administration data was approved in November 2024. The vaccine is commercially marketed in the U.S. and globally.

The Two-Sided Case

▲ Bull Case3
ProQuad is the only MMRV combination vaccine available in the U.S. that offers both subcutaneous and intramuscular administration routes, giving it a convenience edge over GSK's Priorix (subcutaneous only).
The November 2024 FDA supplement approval for concomitant administration data supports broader co-administration with other routine childhood vaccines, which could support stable utilization.
As a well-established branded vaccine with decades of safety data, ProQuad benefits from routine CDC-recommended childhood immunization schedules and public health mandates.
▼ Bear Case4
ProQuad is a tiny revenue contributor for Merck (the entire MMRV franchise is ~$538M vs. Merck's ~$67B total revenue), so even major label changes have negligible impact on MRK's stock.
The vaccine faces potential competition from GSK's Priorix, which is also an MMRV vaccine.
As a live-virus vaccine, ProQuad carries a black-box warning about febrile seizures in children 12-23 months, which could affect uptake versus separate MMR and varicella shots.
Pediatric vaccination rates can fluctuate with public health policy changes, vaccine hesitancy, or shifts in CDC recommendations, none of which Merck controls.

Upcoming Catalysts

  • No hard, dated catalysts (PDUFA, AdComm, or pivotal readout) are scheduled for ProQuad in the next 12 months. The drug is a mature, approved product with no pending regulatory events.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 10

Hover a chip for the title
1 fda.gov2 merck.com3 fda.gov4 fiscal.ai5 merckvaccines.com6 merckvaccines.com7 purplebooksearch.fda.gov8 drugs.com9 stockanalysis.com10 cnbc.com